Biomedical Frontiers, Inc. has developed an iron chelator designed to transform the lives of patients with iron overload. The company has successfully completed initial Phase Ib clinical testing in a small number of iron overload patients with promising results. If additional clinical trials are successful, this chelator, starch-conjugated (S-DFO), will offer patients the hope of a safe, easy, once-a-week single infusion therapy.